Biotron Limited Advances HIV-1 Treatment and Expands Viral Disease Programs

Biotron Limited ( (AU:BIT) ) has issued an update.

Biotron Limited announced the successful completion of its BIT225 HIV-1 Phase 2 clinical trials, which met primary objectives by demonstrating safety and efficacy. The company is advancing its Hepatitis B and Dengue Virus programs, highlighting its potential across multiple infectious diseases. Biotron is also collaborating with C14 Consulting Group to secure strategic partnerships and commercialize its clinical and pre-clinical assets. Additionally, a Share Purchase Plan is being offered to eligible shareholders, providing an opportunity to participate in Biotron’s growth.

More about Biotron Limited

Biotron Limited is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical needs. The company is developing BIT225 for HIV-1 and SARS-CoV-2, and has a promising preclinical program for Hepatitis B Virus. Biotron also focuses on designing drugs that target viroporins, which play a key role in the virus life cycle of various viruses, including Coronavirus, Dengue, Ebola, and others.

YTD Price Performance: 390.0%

Average Trading Volume: 23,250

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: $4.58M

For detailed information about BIT stock, go to TipRanks’ Stock Analysis page.